News in other languages : Biosynex

08-07	Bourse : Eutelsat souffre, la tech américaine s'offre un baroud d'honneur nocturne
08-07	L'énigmatique Mister Warsh, le marché du travail et les taux
08-06	Biosynex victime d'une cyberattaque, l'activité opérationnelle préservée
08-06	BIOSYNEX SA: Cyberattaque
07-22	BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2026 : 44,1 M€ - PERSPECTIVES

More news

Managers and Directors : Biosynex

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	23/06/2015
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	31/12/2014
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	23/06/2015
Thomas Lamy BRD	Director/Board Member	-	23/06/2015
Larry Abensur CHM	Chairman	71	23/06/2015

More insiders

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-2.17%	-2.81%	-23.40%	-91.41%	19.25M
GUARDANT HEALTH, INC.	-4.17%	-5.38%	+150.50%	+322.55%	21.67B
BIOMÉRIEUX	-0.33%	+1.01%	-36.12%	-21.75%	10.28B
10X GENOMICS, INC.	-5.10%	-5.50%	+330.95%	+30.27%	8.02B
CARIS LIFE SCIENCES, INC.	-2.84%	-2.44%	-32.96%	-	7.24B
LANTHEUS HOLDINGS, INC.	+0.30%	+0.80%	+81.57%	+51.76%	6.58B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+2.72%	+0.56%	-11.59%	-13.28%	6.09B
DIASORIN S.P.A.	-0.49%	+1.97%	-10.91%	-19.13%	4.4B
ANDON HEALTH CO., LTD.	-2.23%	-4.02%	+71.41%	+102.27%	4.23B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.34%	-4.42%	-18.97%	-26.20%	2.81B
Average	-1.56%	-1.31%	+50.05%	+37.23%	7.13B
Weighted average by Cap.	-2.13%	-2.11%	+83.71%	+117.67%

See all sector performances

Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	€0.9000	-2.17%	3,237
27/08/26	€0.9200	+2.68%	17,041
26/08/26	€0.8960	-0.67%	4,358
25/08/26	€0.9020	-1.53%	2,303
24/08/26	€0.9160	-1.08%	10,218

Real-time Euronext Paris

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Euronext Paris 16:55:00 28/08/2026 BST			5-day change	1st Jan Change
0.9000 ^EUR	-2.17%		-2.81%	+51.01%

08-06	Biosynex hit by cyberattack, operational activity remains intact
06-11	Triple update for Biosynex

Market Cap	16.59M 19.25M 15.55M 14.2M 26.75M 1.84B 26.83M 185M 72M 929M 72.28M 70.71M 3.08B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.78M 80.98M 65.42M 59.72M 113M 7.74B 113M 776M 303M 3.91B 304M 297M 12.95B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

08-06	Biosynex hit by cyberattack, operational activity remains intact
06-11	Triple update for Biosynex
06-10	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant

23/10/24	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
27/04/23	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
13/04/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
15/03/23	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
31/01/23	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Share Price

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation : Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases : Biosynex

News in other languages : Biosynex

Quotes and Performance

Price Extremes

Managers and Directors : Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

1 day	-2.17%
1 week	-2.81%
Current month	-2.17%
1 month	-2.17%
3 months	-15.09%
6 months	-3.43%
Current year	+51.01%

1 week	0.89	0.92
1 month	0.89	1
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	10.9
5 years	0.46	28.78
10 years	0.46	30.38

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/02/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
15/02/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
28/02/22	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

	2024	2025
Net sales	101M 117M 94.85M 86.59M 163M 11.22B 164M 1.13B 439M 5.66B 441M 431M 18.78B	95.19M 110M 89.25M 81.48M 153M 10.56B 154M 1.06B 413M 5.33B 415M 406M 17.67B
Net income	-43.33M -50.29M -40.63M -37.09M -69.87M -4.81B -70.09M -482M -188M -2.43B -189M -185M -8.04B	-58.22M -67.57M -54.59M -49.83M -93.88M -6.46B -94.18M -648M -253M -3.26B -254M -248M -10.81B
Net Debt	52.94M 61.43M 49.63M 45.31M 85.35M 5.87B 85.62M 589M 230M 2.96B 231M 226M 9.83B	53.19M 61.73M 49.87M 45.52M 85.76M 5.9B 86.03M 592M 231M 2.98B 232M 227M 9.87B